Phase II ELMWOOD trial shows elafibranor is well tolerated and improves liver biochemistry and pruritus in primary sclerosing ...

A multicenter study led by UC Davis Health has tested a new treatment designed to improve care for people with a rare liver ...

Nebokitug is a lab-engineered antibody that targets a molecule called CCL24, a signaling protein known to drive inflammation ...

Study identifies promising new treatment effective against rare liver disease A new experimental therapy may finally offer ...

Researchers have reported encouraging results from a clinical trial of a new monoclonal antibody therapy for primary ...

While Newsmax's revenue is increasing by low single-digit percentages, Mirum's revenue soared 47% year-over-year in the third quarter. This impressive performance was driven by fast-growing sales of ...

PSC occurs in 1 out of 10,000 people, who are mostly male adults between 30 and 60 years old, and it commonly develops in patients with inflammatory bowel disease who have ulcerative colitis. The lack ...

Researchers report promising results for nebokitug, a monoclonal antibody tested for primary sclerosing cholangitis. In a Phase 2 trial, the drug proved safe and showed signs of reducing liver ...

We independently evaluate all of our recommendations. If you click on links we provide, we may receive compensation. Myles is a former senior insurance editor for Investopedia. He oversaw the strategy ...

Julia Kagan is a financial/consumer journalist and former senior editor, personal finance, of Investopedia. Group term life insurance is a temporary insurance policy offered primarily through ...